|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.82 USD | -0.81% |
|
-7.88% | -17.30% |
| 02-23 | Morgan Stanley Lifts Price Target on PTC Therapeutics to $92 From $90, Keeps Overweight Rating | MT |
| 02-20 | RBC Cuts Price Target on PTC Therapeutics to $82 From $87, Keeps Sector Perform Rating | MT |
| Capitalization | 5.2B 4.48B 4.05B 3.88B 7.08B 478B 7.41B 47.84B 19.17B 229B 19.52B 19.1B 820B | P/E ratio 2026 * |
-122x | P/E ratio 2027 * | 38.4x |
|---|---|---|---|---|---|
| Enterprise value | 3.48B 3B 2.71B 2.6B 4.75B 320B 4.97B 32.06B 12.84B 154B 13.08B 12.8B 549B | EV / Sales 2026 * |
3.55x | EV / Sales 2027 * | 2.85x |
| Free-Float |
97.66% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PTC Therapeutics, Inc.
| 1 day | -0.81% | ||
| 1 week | -7.88% | ||
| Current month | -7.88% | ||
| 1 month | -15.88% | ||
| 3 months | -18.32% | ||
| 6 months | +10.31% | ||
| Current year | -17.30% |
| 1 week | 61.43 |  | 67.07 |
| 1 month | 61.43 | | 74.58 |
| Current year | 61.43 | | 80.18 |
| 1 year | 35.95 | | 87.5 |
| 3 years | 17.53 | | 87.5 |
| 5 years | 17.53 | | 87.5 |
| 10 years | 4.03 | | 87.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 54 | 21/03/2023 |
Pierre Gravier
DFI | Director of Finance/CFO | 41 | 12/07/2023 |
Lee Golden
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 31/10/2004 | |
Allan Jacobson
BRD | Director/Board Member | 80 | 30/03/1998 |
David Southwell
BRD | Director/Board Member | 65 | 30/11/2005 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.81% | -7.88% | +19.45% | +30.36% | 5.2B | |
| +0.72% | -5.86% | +13.89% | +216.87% | 885B | |
| +0.32% | -3.23% | +44.22% | +57.17% | 579B | |
| -0.96% | -0.85% | +7.38% | +53.82% | 407B | |
| -2.93% | -7.03% | +11.14% | +28.39% | 350B | |
| -0.81% | -5.55% | +22.14% | +56.82% | 302B | |
| -2.74% | -6.70% | +20.11% | +33.99% | 301B | |
| -0.24% | -6.49% | +22.33% | +6.94% | 286B | |
| +0.53% | -4.80% | +13.75% | +61.77% | 199B | |
| -0.83% | -3.37% | +22.59% | +79.46% | 179B | |
| Average | -0.79% | -5.18% | +19.70% | +62.56% | 349.39B | |
| Weighted average by Cap. | -0.52% | -4.87% | +20.27% | +89.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 981M 845M 763M 732M 1.34B 90.12B 1.4B 9.02B 3.61B 43.22B 3.68B 3.6B 155B | 1.16B 1B 906M 869M 1.59B 107B 1.66B 10.71B 4.29B 51.31B 4.37B 4.28B 184B |
| Net income | -66.01M -56.91M -51.37M -49.29M -89.89M -6.07B -94.07M -607M -243M -2.91B -248M -242M -10.4B | 89.51M 77.18M 69.67M 66.85M 122M 8.23B 128M 824M 330M 3.94B 336M 329M 14.11B |
| Net Debt | -1.72B -1.48B -1.34B -1.28B -2.34B -158B -2.44B -15.78B -6.32B -75.59B -6.44B -6.3B -270B | -1.88B -1.62B -1.46B -1.4B -2.56B -173B -2.68B -17.31B -6.93B -82.9B -7.06B -6.91B -296B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/03/26 | 62.82 $ | -0.81% | 1,225,424 |
| 05/03/26 | 63.33 $ | -1.49% | 1,137,040 |
| 04/03/26 | 64.29 $ | -0.16% | 1,246,659 |
| 03/03/26 | 64.39 $ | -2.98% | 1,312,066 |
| 02/03/26 | 66.37 $ | -2.67% | 1,949,490 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PTCT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition